Small molecule inhibitor targeting the Hsp70-Bim protein–protein interaction in estrogen receptor-positive breast cancer overcomes tamoxifen resistance

Small molecule inhibitor targeting the Hsp70-Bim protein–protein interaction in estrogen receptor-positive breast cancer overcomes tamoxifen resistance

Abstract Introduction Estrogen receptor (ER) positive patients compromise about 70% of breast cancers. Tamoxifen, an antagonist of ERα66 (the classic ER), is the most effective and the standard first-line drug. However, its efficacy is limited by the development of acquired resistance. Methods A spe...

Full description

Bibliographic Details
Main Authors: Ting Song, Hong Zhang, Qicheng Zhao, Zhiyuan Hu, Ziqian Wang, Yang Song, Zhichao Zhang
Format: Article
Language:English
Published: BMC 2024-02-01
Series:Breast Cancer Research
Subjects:
Hsp70-Bim PPI
Hsp70-Bag3 PPI
Tamoxifen resistance
Estrogen receptor α36 (ERα36)
S1g-2
Online Access:https://doi.org/10.1186/s13058-024-01790-0

Internet

https://doi.org/10.1186/s13058-024-01790-0

Similar Items